^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    S-588210

    i
    Other names: S-588210, S 588210, Multipeptide vaccine S-588210, S-488210/Montanide, S-488210/S-488211, S-488211/Montanide, S588210, S488210/S488211, S 488210/S 488211
    Associations

    News

    Trials
    Company:
    OncoTherapy, Shionogi, University of Chicago
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    over2years
    DURANCE: DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr (clinicaltrials.gov)
    P1/2, N=64, Recruiting, University College, London | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02:01 • HLA-A*02
    |
    Imfinzi (durvalumab) • S-588210
    almost3years
    DURANCE: DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr (clinicaltrials.gov)
    P1/2, N=64, Not yet recruiting, University College, London | Trial completion date: Sep 2028 --> Mar 2029 | Trial primary completion date: Aug 2024 --> Mar 2025
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02:01 • HLA-A*02
    |
    Imfinzi (durvalumab) • S-588210
    over3years
    DURANCE: DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr (clinicaltrials.gov)
    P1/2, N=64, Not yet recruiting, University College, London | Trial completion date: Jul 2027 --> Sep 2028 | Trial primary completion date: Jul 2023 --> Aug 2024
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    Imfinzi (durvalumab) • S-588210
    almost5years
    DURANCE: DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr (clinicaltrials.gov)
    P1/2, N=64, Not yet recruiting, University College, London | Initiation date: Dec 2019 --> Mar 2020
    Clinical • Trial initiation date • Combination therapy
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    Imfinzi (durvalumab) • S-588210